Introduction
============

Over 70% of new cases of nasopharyngeal cancer (NPC) are locoregionally advanced NPC (LANPC; stage III-IV, without distant metastasis) \[[@b1-crt-2017-255]\]. Concurrent chemoradiotherapy (CCRT)±adjuvant chemotherapy is the mainstay treatment. Compared to additional adjuvant chemotherapy, induction chemotherapy (IC) results in early eradication of micrometastases and fewer toxicities; therefore, IC+CCRT is a promising strategy \[[@b2-crt-2017-255]\].

Myelosuppression (e.g., neutropenia, anemia, thrombocytopenia) is a major chemotherapy side-effect that increases morbidity/mortality and health-care costs \[[@b3-crt-2017-255]\]. In clinical practice, 30% of patients experience severe/febrile neutropenia during chemotherapy, two-thirds during the first cycle \[[@b4-crt-2017-255]\]. The timing of chemotherapy-induced neutropenia (CIN) may affect prognosis \[[@b5-crt-2017-255],[@b6-crt-2017-255]\]. Therefore, it is essential to explore the occurrence of CIN and its value in predicting prognosis. However, studies investigating the prognostic value of CIN over multiple cycles on survival in lung/esophageal/colorectal/gynecological cancer have generated positive \[[@b7-crt-2017-255],[@b8-crt-2017-255]\], mixed \[[@b9-crt-2017-255]\], non-significant \[[@b10-crt-2017-255],[@b11-crt-2017-255]\] and negative results \[[@b12-crt-2017-255],[@b13-crt-2017-255]\]. Moreover, CIN after the first cycle has been suggested to indicate chemotherapy resistance, future complications, and poor prognosis \[[@b14-crt-2017-255],[@b15-crt-2017-255]\].

CIN may reflect sufficient chemotherapeutic dose, enhanced effectiveness and active tumor response \[[@b9-crt-2017-255],[@b10-crt-2017-255],[@b12-crt-2017-255]\]. Alternatively, CIN may reduce host immune function, attenuate resistance to malignant transformation and promote cancer development and progression \[[@b12-crt-2017-255],[@b13-crt-2017-255],[@b16-crt-2017-255]\]. Neutrophilto-lymphocyte ratio (NLR) is a novel joint biomarker, which can comprehensively reflect the level of patients' inflammation and immune function; higher pretreatment NLR has been reported to have association with poorer survival in cancer patients \[[@b17-crt-2017-255],[@b18-crt-2017-255]\]. However, it still remains unclear whether CIN and post-treatment NLR (post-NLR) can influence survival; no publication has explored this issue in NPC. Moreover, neutropenia during the first cycle of induction chemotherapy (IC-1) merits special attention, as it could indicate high-risk patients who require timely targeted interventions and intensive treatment evaluations.

The primary aim of this study was to investigate the associations between the occurrence and grade of neutropenia during IC-1 and survival in patients with LANPC undergoing IC+CCRT. The secondary aims were to assess the occurrence of myelosuppression events and post-NLR after IC-1 and explore whether the timing of neutropenia, number of myelosuppression events, and high post-NLR could influence survival.

Materials and Methods
=====================

1. Patient
----------

Consecutive patients (n=2,191) with newly-diagnosed, non-metastatic, pathologically proven NPC who received radical treatment based on intensity-modulated radiotherapy (IMRT) at Sun Yat-sen University Cancer Center (SYSUCC) between November 2009 and May 2012 in a prospectively maintained database (cutoff time, December 31, 2016) were assessed. As this was a real-world study, we included patients with comorbidities, alcohol consumption, and advanced age \[[@b19-crt-2017-255]\], via loose eligibility criteria: (1) patients diagnosed with LANPC; (2) patients who underwent IC+CCRT; (3) age of diagnosis ≥ 18 years-old; (4) no prophylactic use of granulocyte colony-stimulating factor (G-CSF) during IC-1; (5) detailed information on IC-1--induced myelosuppression and other covariates can be collected from the database; 545 patients (24.9%) were included ([S1 Fig.](#SD1-crt-2017-255){ref-type="supplementary-material"}). This study was approved by the Institutional Review Board and Ethics Committee of SYSUCC; the need for informed consent was waived. The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform (<http://www.researchdata.org.cn>), with the approval RDD number as RDDA2017000145.

2. Examination, treatment and follow-up
---------------------------------------

The following examinations were routinely implemented within the 2-to-4 weeks prior to IC-1: complete medical history, physical examination, blood and biochemistry tests, nasoendoscopy, neck and nasopharyngeal magnetic resonance imaging, chest radiography, abdominal ultrasonography and whole-body bone scan; ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography was performed for 187/545 patients (34.3%) at initial evaluation. Moreover, the tumor-related biomarkers, i.e., plasma Epstein-Barr virus (EBV) DNA titer, IgA antibodies against viral capsid antigen (VCA-IgA) and early antigen (EA-IgA), were quantified before treatment.

IC was PF (80 mg/m^2^ cisplatin, 4,000 mg/m^2^ 5-fluorouracil), TP (75 mg/m^2^ docetaxel, 75 mg/m^2^ cisplatin), or TPF (60 mg/m^2^ docetaxel, 60 mg/m^2^ cisplatin, 3,000 mg/m^2^ 5-fluorouracil) every 3 weeks for 2-4 cycles. The timing of initiation of CCRT is on day 21 after completion of IC. Concurrent chemotherapy was cisplatin (30-40 mg/m^2^) weekly, or cisplatin (80-100 mg/m^2^) every 3 weeks concurrently with IMRT. Full details are provided in the [Supplementary Methods](#SD2-crt-2017-255){ref-type="supplementary-material"}.

3. Assessment of neutropenia during IC-1
----------------------------------------

All patients underwent weekly blood and biochemistry tests for safety surveillance during the 21-day IC-1 cycle. G-CSF was provided whenever possible for patients suffering grade 3-4/febrile neutropenia; additional blood tests were used to monitor recovery status. Each patient had at least three tests during IC-1.

Myelosuppression events was classified using National Cancer Institute Common Terminology Criteria for Adverse Events (ver. 4.0) based on nadir absolute neutrophil count (ANC), hemoglobin concentration (Hb), and platelet count (PLT). Neutropenia was categorized as no neutropenia (shown as 'absent' in figures/tables; ANC ≥ 2.0×10^9^/L), grade 1-2 (1.0×10^9^/L ≤ ANC \< 2.0×10^9^/L) or grade 3-4 (ANC \< 1.0×10^9^/L); anemia, nadir Hb \< 115.0 g/L; and thrombocytopenia, nadir PLT \< 100.0×10^9^/L. Timing of neutropenia was classified as: first (days 1-7), second (days 8-14), and third (days 15-21) week of IC-1. Number of myelosuppression events was classified as: group 1 (none), group 2 (one), and group 3 (two/three). As G-CSF can substantially increase ANC and make the maximal and average value of post-NLR deviate from the real level of natural course, we used the minimal value of post-NLR (post-NLR~min~) to perform analysis. Post-NLR~min~ more than or equal to median was defined as high level.

End-points were overall survival (OS) and disease-free survival (DFS). OS was defined as the duration from the date of treatment to death from any cause or last date known alive. DFS was defined as the duration from the date of treatment to failure (i.e., locoregional relapse and distant metastasis), death or last follow-up, whichever happened first.

4. Statistical analysis
-----------------------

Follow-up was reported as median value and range; categorical variables, as frequencies and percentages. Descriptive statistics provided as continuous variables were converted into categorical variables according to interquartile range (IQR; age at diagnosis), median value (pretreatment NLR and post-NLR~min~), and cutoff value (EBV DNA, VCA-IgA, and EA-IgA), as reported previously \[[@b17-crt-2017-255]\]. Baseline characteristics were compared using the chi-square test; actuarial 5-year OS/DFS, estimated using the Kaplan-Meier method and compared using the log-rank test \[[@b20-crt-2017-255]\]. Neutropenia, anemia, thrombocytopenia, and post-NLR~min~ were considered time-to-event data; cumulative incidences were calculated with the Kaplan-Meier method and compared with the logrank test \[[@b20-crt-2017-255]\], and presented using Microsoft Excel (Microsoft Inc., Redmond, WA).

Significant covariates in univariate analysis were entered into multivariate Cox regression analyses using the backward stepwise algorithm (see [Supplementary Methods](#SD2-crt-2017-255){ref-type="supplementary-material"}). Adjusted hazard ratios (AHRs) and 95% confidence intervals were calculated for multivariate analysis, and presented as forest plots using Microsoft Excel via Neyeloff's method \[[@b21-crt-2017-255]\]. Statistical analyses and figures were generated using SPSS ver. 22.0 (IBM Corp., Armonk, NY), unless otherwise specified. Two-sided p-values of \< 0.05 were considered significant.

Results
=======

1. Baseline characteristics
---------------------------

Median age of the 545 eligible patients was 45 years (IQR, 37 to 52) ([Table 1](#t1-crt-2017-255){ref-type="table"}); male-to-female ratio was approximately 3:1; 163/545 patients (29.9%) had at least one comorbidity; and 519/545 (95.2%) had non-keratinizing undifferentiated NPC (i.e., World Health Organization \[WHO\] histologic type III), typical of the endemic area. Most patients received TPF (42.2%) or TP regimen (35.6%); 22.2% received PF. All baseline characteristics were well-balanced between patients with no neutropenia, grade 1-2 and grade 3-4 neutropenia, except for chemotherapy regimen (p \< 0.001). After median follow-up of 63 months (range, 1 to 85 months), 97/545 patients (17.8%) had died; 60/545 (11.0%) and 90/545 (16.5%) developed locoregional relapse and distant metastases, respectively.

2. Association between grade of neutropenia and survival
--------------------------------------------------------

Patients without neutropenia had better OS/DFS than patients with grade 1-2 (p=0.010 and p=0.011) and grade 3-4 (p=0.001 and p=0.021) neutropenia ([Fig. 1](#f1-crt-2017-255){ref-type="fig"}). OS/DFS were not significantly different between grade 1-2 and grade 3-4 neutropenia (p=0.420 and p=0.952). Similar results were observed in the subgroup receiving PF. Patients receiving TPF had equivalent OS/DFS, regardless of no/grade 1-2/grade 3-4 neutropenia (all p \> 0.05). For patients receiving TP, no neutropenia was associated with better OS/DFS vs. grade 3-4 neutropenia (p=0.026 and p=0.037) but not vs. grade 1-2 neutropenia.

In univariate analysis, WHO histologic type I-II, EBV DNA titer ≥ 100,000 copies/mL, clinical stage IVA, and grade 1-2/grade 3-4 neutropenia were associated with poor OS/DFS; NLR ≥ 2.35 was also associated with poor DFS (all p \< 0.05) ([Table 2](#t2-crt-2017-255){ref-type="table"}). All aforementioned variables retained independent significance after adjustment in multivariate analysis (all p \< 0.05) ([Table 2](#t2-crt-2017-255){ref-type="table"}). Notably, OS/DFS were not significantly different between patients with grade 1-2 vs. 3-4 neutropenia (p=0.395 and p=0.810).

3. Occurrence of myelosuppression and post-NLR~min~ during IC-1
---------------------------------------------------------------

The cumulative incidence of neutropenia, anemia, thrombocytopenia, and high post-NLR~min~ (≥ 1.33) was 53.58%, 48.81%, 6.61%, and 51.01% on the 21st day of IC-1. The incidence of neutropenia sharply increased on days 5-10, then continued to gradually increase; the incidence of anemia and high post-NLR~min~ gradually increased; and the incidence of thrombocytopenia remained low but gradually increased over the 21-day cycle of IC-1 ([Fig. 2A](#f2-crt-2017-255){ref-type="fig"}). TPF regimen was more likely to lead to neutropenia compare with TP (p=0.049) and PF (p=0.001). The trend of cumulative incidence of myelosuppression events and high post-NLR~min~ were in accordance with the frequency distributions in [Fig. 2B](#f2-crt-2017-255){ref-type="fig"}. Simultaneous multiple myelosuppression events were more likely to occur in the second week of IC-1, while high post-NLR~min~ tended to occur in the third week of IC-1.

4. Effect of IC-1--induced neutropenia, timing of neutropenia, number of myelosuppression events, and high post-NLR~min~ on survival
------------------------------------------------------------------------------------------------------------------------------------

As patients with grade 1-2 and 3-4 neutropenia had comparable survival outcomes, these groups were combined to a single neutropenia group. Univariate analysis ([Table 3](#t3-crt-2017-255){ref-type="table"}) revealed neutropenia had a negative effect on OS/DFS vs. no neutropenia (p=0.001 and p=0.005). Patients with neutropenia had almost 10% lower 3/5-year OS/DFS than patients without neutropenia. Significantly poorer OS/DFS were observed for patients with neutropenia during the first, second, and third weeks of IC-1 vs. no neutropenia (all p \< 0.05), with the exception of "second week" vs. "absent" for DFS; "second week" was associated with higher 3/5-year OS/DFS than "first week"/"third week," though the differences were non-significant (all p \> 0.05). Group 3 had significantly poorer OS/DFS than group 1 (p=0.029 and p=0.050); no significant differences in OS/DFS existed between group 1 and group 2 (p=0.362 and p=0.747). Patients with post-NLR~min~ ≥ 1.33 had poorer DFS (p=0.016) and equivalent OS (p=0.087) compared to patients with post-NLR~min~ \< 1.33.

In multivariate analysis, AHRs for OS (DFS) were adjusted for WHO histologic type, EBV DNA titer and clinical stage (all of these covariates plus NLR) ([Fig. 3A](#f3-crt-2017-255){ref-type="fig"}-[F](#f3-crt-2017-255){ref-type="fig"}). The threeweeks classification failed to separate OS/DFS (all p \> 0.05). Two/three myelosuppression events was validated as negative prognostic factor for OS/DFS (p=0.018 and p=0.033); high post-NLR~min~ (≥ 1.33) was only significant in predicting poor DFS (p=0.029). We included timing of neutropenia (absent/first/second/third week), IC-1--induced anemia and thrombocytopenia (absent/occurred), and post-NLR~min~ (≥ 1.33/\< 1.33) as covariates in additional multivariate analysis. Neutropenia had a negative effect on OS (AHR, 2.44; p \< 0.001) and DFS (AHR, 2.05; p \< 0.001) ([Fig. 4](#f4-crt-2017-255){ref-type="fig"}). Similar effects were observed in patients receiving PF (OS, p=0.046; DFS, p=0.001) or TP (DFS, p=0.004), but not TPF (OS, p=0.906; DFS, p=0.671) ([Fig. 4](#f4-crt-2017-255){ref-type="fig"}).

Discussion
==========

This first attempt to explore the prognostic value of the occurrence and severity of IC-1--induced neutropenia in LANPC validated two/three myelosuppression events and high post-NLR~min~ have significant negative effects on OS and/or DFS; the timing of neutropenia had no significant effect. This information could improve prognostication and selection of high-risk patients, and indicate some possible clinical implications. Routine blood test (RBT) is widely used in primary, secondary, and even tertiary hospitals; the diagnostic criteria for each item of RBT are basically identical among different hospitals. Moreover, RBT is suitable for almost all patients, because of its low price, simplicity, and safety. Thus, dynamic monitoring of ANC, lymphocyte, Hb, and PLT over the whole course of treatment is convenient and has clinical applicability. Patients who experience neutropenia or improved post-NLR~min~ during IC-1 can be screened out as early as possible. After comprehensive evaluation, those high-risk patients can receive timely supportive treatment, targeted interventions (e.g., prophylactic G-CSF in future cycles), and modification of treatment (e.g., reducing chemotherapy dose), with the aim of improving patients' survival benefits.

Several pretreatment inflammatory-immune biomarkers can predict prognosis, such as NLR, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio \[[@b22-crt-2017-255]-[@b24-crt-2017-255]\]. Of which, pretreatment NLR can predict survival outcomes and has been used to generate predictive nomograms in NPC \[[@b17-crt-2017-255],[@b25-crt-2017-255]\]. Elevated pretreatment NLR indicates a disordered immune response, which is associated cancer development and progression \[[@b18-crt-2017-255]\]. However, the relationship between post-treatment inflammatory-immune biomarkers (e.g., CIN and post-NLR) and survival remains crude. Although previous studies explored the prognostic value of CIN in other cancers, few focused on IC-1--induced neutropenia \[[@b7-crt-2017-255]-[@b13-crt-2017-255]\]. Moreover, the design of these studies limits their reliability and applicability; for example, strict inclusion/exclusion criteria (e.g., age ≥ 70 years \[[@b8-crt-2017-255]\]), landmark/subset analysis (i.e., only subgroups analyzed \[[@b7-crt-2017-255],[@b9-crt-2017-255],[@b10-crt-2017-255]\]) and missing pretreatment NLR data. These factors may also explain the positive \[[@b7-crt-2017-255],[@b8-crt-2017-255]\], mixed \[[@b9-crt-2017-255]\], non-significant \[[@b10-crt-2017-255],[@b11-crt-2017-255]\], and negative results \[[@b12-crt-2017-255],[@b13-crt-2017-255]\] of the aforementioned studies. Therefore, this real-world study including data on comprehensive pretreatment biomarkers (e.g., NLR, EBV DNA titer, VCA-IgA, and EA-IgA) provides a robust assessment of the associations between IC-1--induced neutropenia and survival in LANPC.

IC-1--induced neutropenia, but not the timing of neutropenia, had prognostic value for poor survival in patients with LANPC receiving TP/PF. In contrast, previous studies suggested CIN after multiple chemotherapy cycles \[[@b7-crt-2017-255],[@b8-crt-2017-255]\] and early-onset \[[@b5-crt-2017-255],[@b6-crt-2017-255]\] were associated with a better prognosis. There are three possible explanations for these discrepancies. First, CIN after multiple cycles was regarded as an indicator of high drug activity and excellent treatment efficiency \[[@b7-crt-2017-255]\]. Patients with CIN were considered to have revived more intensive treatment and therefore achieve better survival outcomes. However, a higher dose of chemotherapy does not always improve prognosis. Peng et al. \[[@b26-crt-2017-255]\] reported a high cumulative cisplatin dose (≥ 240 mg/m^2^) did not improve OS/DFS (vs. low cumulative dose) in LANPC. Moreover, it is inappropriate to evaluate the cumulative dose and intensity after only the first cycle of IC. Hence, IC-1--induced neutropenia has limited ability to indicate treatment efficacy. Second, chemotherapy-related hematological toxicities, such as myelosuppression events and lymphopenia, can indicate deterioration of host immune function. Past evidences have reported that immunosuppressive agents increase cancer risk in patients receiving renal transplants, while additional immunestimulants improve survival in advanced Ewing sarcoma \[[@b16-crt-2017-255],[@b27-crt-2017-255]\]. Although neutropenia can easily lead to low post-NLR~min~, we cannot simply assume that the negative effect of neutropenia is contradictory to the positive effect of low post-NLR~min~, since post-NLR~min~ is a joint biomarker and determined by neutrophil and lymphocyte counts. In our study, only 72.7% of patients with low post-NLR~min~ experienced IC-1--induced neutropenia; the remaining patients had normal ANC and elevated lymphocyte counts. Among patients with NPC treated by CCRT alone, treatment-related lymphopenia was associated with poorer survival and higher risk of death, disease progression, and distant metastasis \[[@b28-crt-2017-255]\]. Thus, patients with IC-1--induced neutropenia and/or high post-NLR~min~ are predisposed to vulnerable host immune function, indicating poorer survival. Third, we only analyzed myelosuppression events during the 21-day cycle of IC-1; the aforementioned studies with positive results undertook longer observations over more than two cycles.

Interestingly, IC-1--induced neutropenia was not associated with survival among patients receiving TPF. The TPF regimen, a potent IC based on three chemotherapeutic agents, has demonstrated promising results in LANPC \[[@b2-crt-2017-255]\]. TPF takes longer to administer than TP, since 5-fluorouracil is given via continuous intravenous infusion on days 1-5, while docetaxel and cisplatin are administered on day 1. Moreover, our study showed that TPF IC-1 can lead to significantly higher incidence of neutropenia than PF/TP regimen ([Fig. 2A](#f2-crt-2017-255){ref-type="fig"}). Therefore, in clinical practice, patients receiving TPF usually receive from more meticulous nursing care, longer observation, and additional supportive treatments. Such intensive management may help to prevent further deterioration and promote recovery. Meanwhile, the relationship between TPF IC-1--induced neutropenia and survival was influenced, to some extent, by those medical interventions.

This study has several limitations. First, although we included pretreatment NLR and post-NLR~min~, the optimal cutoff has not been identified. For pretreatment NLR, different research centers use varied levels, including 2.70 \[[@b29-crt-2017-255]\], 3.00 \[[@b24-crt-2017-255]\], and 3.73 \[[@b30-crt-2017-255]\]. Moreover, not all cutoff values were proven significant \[[@b24-crt-2017-255]\]. Although we used and validated the median of pretreatment NLR and post-NLR~min~ as the cutoff for DFS, these values failed to significantly discriminate different OS. Similarly, standardized procedures and assay harmonization for pretreatment EBV DNA are not yet established. Thus, cutoff selection may result in bias and error. Second, the sample sizes for certain subgroups were relatively small, especially patients receiving PF (neutropenia, n=43; absent, n=78) and with neutropenia in the third week (n=54). Future large-scale prospective studies are required to further address this issue. Last but not least, although RBTs were required once a week, the precise timings varied from person to person, which may modify the distribution of myelosuppression.
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![Kaplan-Meier survival curves for overall survival (A-D) and disease-free survival (E-H) stratified by grade of neutropenia. The columns represent subgroups receiving PF (B, F), TPF (C, G), and TP (D, H), respectively. PF, cisplatin--5-fluorouracil; TPF, docetaxel--cisplatin--5-fluorouracil; TP, docetaxel--cisplatin.](crt-2017-255f1){#f1-crt-2017-255}

![Cumulative incidence rate (A) and frequency distribution (B) of myelosuppression events and minimal value of the post-treatment neutrophil-to-lymphocyte ratio (post-NLR~min~). (A) Kaplan-Meier estimates of the time-to-occurrence over the 21-day cycle of the first cycle of induction chemotherapy (IC-1). (B) Histogram and line chart of number of patients suffering myelosuppression events and high post-NLR~min~ in first/second/third weeks of IC-1. TPF, docetaxel--cisplatin--5-fluorouracil; TP, docetaxel--cisplatin; PF, cisplatin--5-fluorouracil.](crt-2017-255f2){#f2-crt-2017-255}

![Kaplan-Meier survival curves for overall survival (A, C, E) and disease-free survival (B, D, F) after adjustment for covariates. Patients were stratified by timing of neutropenia (absent and first/second/third week of the first cycle of induction chemotherapy) (A, B), number of myelosuppression events (group 1, none; group 2, one; group 3, two/three) (C, D), and minimal value of the post-treatment neutrophil-to-lymphocyte ratio (post-NLR~min~, \< 1.33 and ≥ 1.33) (E, F). p-values for overall survival (disease-free survival) were calculated using multivariate Cox regression analyses adjusted for World Health Organization histologic type, Epstein-Barr virus DNA titer and clinical stage (all of these covariates plus neutrophil-to-lymphocyte ratio).](crt-2017-255f3){#f3-crt-2017-255}

![Forest plots depicting adjusted hazard ratios (AHRs) (squares) and 95% confidence intervals (CIs) (bars) of the association between the first-cycle of induction chemotherapy (IC-1)--induced neutropenia and overall/disease-free survival. Blue and red squares individually indicate all patients and subgroups receiving different regimens. AHRs for overall survival (disease-free survival) was adjusted for timing of neutropenia, IC-1--induced anemia, IC-1--induced thrombocytopenia, minimal value of the post-treatment neutrophil-to-lymphocyte ratio, World Health Organization histologic type, Epstein-Barr virus DNA titer and clinical stage (all covariates plus neutrophil-to-lymphocyte). Ref., reference; PF, cisplatin--5-fluorouracil; TPF, docetaxel--cisplatin--5-fluorouracil; TP, docetaxel--cisplatin.](crt-2017-255f4){#f4-crt-2017-255}

###### 

Baseline characteristics of patients

  Characteristic                                                                              No. (%)^[a)](#tfn1-crt-2017-255){ref-type="table-fn"}^ (n=545)   First-cycle induction chemotherapy-induced neutropenia   p-value                   
  ------------------------------------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------- ------------ ------------ ----------
  **Age at diagnosis (yr)**                                                                                                                                                                                                                       
   18-36                                                                                      121 (22.2)                                                       60 (23.7)                                                43 (23.6)    18 (16.4)    0.321
   37-44                                                                                      138 (25.3)                                                       59 (23.3)                                                53 (29.1)    26 (23.6)    
   45-51                                                                                      135 (24.8)                                                       63 (24.9)                                                44 (24.2)    28 (25.5)    
   ≥ 52                                                                                       151 (27.7)                                                       71 (28.1)                                                42 (23.1)    38 (34.5)    
  **Sex**                                                                                                                                                                                                                                         
   Male                                                                                       418 (76.7)                                                       204 (80.6)                                               132 (72.5)   82 (74.5)    0.120
   Female                                                                                     127 (23.3)                                                       49 (19.4)                                                50 (27.5)    28 (25.5)    
  **Family history of cancer**                                                                                                                                                                                                                    
   No                                                                                         412 (75.6)                                                       194 (76.7)                                               138 (75.8)   80 (72.7)    0.720
   Yes                                                                                        133 (24.4)                                                       59 (23.3)                                                44 (24.2)    30 (27.3)    
  **Comorbidity**                                                                                                                                                                                                                                 
   No                                                                                         382 (70.1)                                                       167 (66.0)                                               137 (75.3)   78 (70.9)    0.112
   Yes                                                                                        163 (29.9)                                                       86 (34.0)                                                45 (24.7)    32 (29.1)    
  **Cigarette smoking**                                                                                                                                                                                                                           
   No                                                                                         328 (60.2)                                                       150 (59.3)                                               112 (61.5)   66 (60.0)    0.893
   Yes                                                                                        217 (39.8)                                                       103 (40.7)                                               70 (38.5)    44 (40.0)    
  **WHO histologic type**                                                                                                                                                                                                                         
   Type I-II                                                                                  26 (4.8)                                                         11 (4.3)                                                 8 (4.4)      7 (6.4)      0.680
   Type III                                                                                   519 (95.2)                                                       242 (95.7)                                               174 (95.6)   103 (93.6)   
  **Viral capsid antigen IgA^[b)](#tfn2-crt-2017-255){ref-type="table-fn"}^**                                                                                                                                                                     
   \< 1:80                                                                                    161 (29.5)                                                       72 (28.5)                                                54 (29.7)    35 (31.8)    0.885
   1:80-1:320                                                                                 266 (48.8)                                                       126 (49.8)                                               91 (50.0)    49 (44.5)    
   ≥ 1:640                                                                                    118 (21.7)                                                       55 (21.7)                                                37 (20.3)    26 (23.6)    
  **Early antigen IgA^[b)](#tfn2-crt-2017-255){ref-type="table-fn"}^**                                                                                                                                                                            
   \< 1:10                                                                                    205 (37.6)                                                       95 (37.5)                                                70 (38.5)    40 (36.4)    0.977
   1:10-1:20                                                                                  143 (26.2)                                                       69 (27.3)                                                46 (25.3)    28 (25.5)    
   ≥ 1:40                                                                                     197 (36.1)                                                       89 (35.2)                                                66 (36.3)    42 (38.2)    
  **Epstein-Barr virus DNA titer (copy/mL)^[b)](#tfn2-crt-2017-255){ref-type="table-fn"}^**                                                                                                                                                       
   \< 10,000                                                                                  302 (55.4)                                                       142 (56.1)                                               102 (56.0)   58 (52.7)    0.981
   10,000-99,999                                                                              183 (33.6)                                                       84 (33.2)                                                60 (33.0)    39 (35.5)    
   ≥ 100,000                                                                                  60 (11.0)                                                        27 (10.7)                                                20 (11.0)    13 (11.8)    
  **Neutrophil-to-lymphocyte ratio^[b)](#tfn2-crt-2017-255){ref-type="table-fn"}^**                                                                                                                                                               
   \< 2.35                                                                                    272 (49.9)                                                       128 (50.6)                                               86 (47.3)    58 (52.7)    0.634
   ≥ 2.35                                                                                     273 (50.1)                                                       125 (49.4)                                               96 (52.7)    52 (47.3)    
  **Clinical stage (8th edition)^[c)](#tfn3-crt-2017-255){ref-type="table-fn"}^**                                                                                                                                                                 
   III                                                                                        249 (45.7)                                                       114 (45.1)                                               81 (44.5)    54 (49.1)    0.720
   IVA                                                                                        296 (54.3)                                                       139 (54.9)                                               101 (55.5)   56 (50.9)    
  **T category (8th edition)^[c)](#tfn3-crt-2017-255){ref-type="table-fn"}^**                                                                                                                                                                     
   T1                                                                                         20 (3.7)                                                         3 (1.2)                                                  9 (4.9)      8 (7.3)      0.113
   T2                                                                                         50 (9.2)                                                         25 (9.9)                                                 17 (9.3)     8 (7.3)      
   T3                                                                                         292 (53.6)                                                       137 (54.2)                                               94 (51.6)    61 (55.5)    
   T4                                                                                         183 (33.6)                                                       88 (34.8)                                                62 (34.1)    33 (30.0)    
  **N category (8th edition)^[c)](#tfn3-crt-2017-255){ref-type="table-fn"}^**                                                                                                                                                                     
   N0                                                                                         35 (6.4)                                                         18 (7.1)                                                 10 (5.5)     7 (6.4)      0.928
   N1                                                                                         270 (49.5)                                                       120 (47.4)                                               91 (50.0)    59 (53.6)    
   N2                                                                                         101 (18.5)                                                       50 (19.8)                                                32 (17.6)    19 (17.3)    
   N3                                                                                         139 (25.5)                                                       65 (25.7)                                                49 (26.9)    25 (22.7)    
  **Chemotherapy regimen**                                                                                                                                                                                                                        
   PF                                                                                         121 (22.2)                                                       78 (30.8)                                                31 (17.0)    12 (10.9)    \< 0.001
   TPF                                                                                        230 (42.2)                                                       84 (33.2)                                                88 (48.4)    58 (52.7)    
   TP                                                                                         194 (35.6)                                                       91 (36.0)                                                63 (34.6)    40 (36.4)    

Values are presented as number (%). WHO, World Health Organization; PF, cisplatin--5-fluorouracil; TPF, docetaxel--cisplatin-- 5-fluorouracil; TP, docetaxel--cisplatin.

Percentages may not add up to 100 because of rounding,

All variables were measured before treatment,

8th edition of the Union for International Cancer Control/American Joint Committee on Cancer staging system.

###### 

Univariate and multivariate analysis of the effect of grade of neutropenia on survival

  Variable                                                                                    Overall survival   Disease-free survival                                                                                  
  ------------------------------------------------------------------------------------------- ------------------ ----------------------- ------------------ ---------- ------------------ ---------- ------------------ ----------
  **Age at diagnosis (yr)**                                                                                                                                                                                             
   18-36                                                                                      Reference                                  \-                            Reference                     \-                 
   37-44                                                                                      1.02 (0.56-1.85)   0.952                   \-                 \-         1.19 (0.72-1.96)   0.500      \-                 \-
   45-51                                                                                      1.07 (0.59-1.94)   0.837                   \-                 \-         1.21 (0.73-1.99)   0.459      \-                 \-
   ≥ 52                                                                                       1.37 (0.78-2.40)   0.272                   \-                 \-         1.26 (0.78-2.06)   0.345      \-                 \-
  **Sex**                                                                                                                                                                                                               
   Female vs. male (ref.)                                                                     0.94 (0.59-1.52)   0.808                   \-                 \-         1.06 (0.72-1.56)   0.774      \-                 \-
  **Family history of cancer**                                                                                                                                                                                          
   Yes vs. no (ref.)                                                                          1.01 (0.64-1.60)   0.961                   \-                 \-         0.95 (0.64-1.40)   0.781      \-                 \-
  **Comorbidity**                                                                                                                                                                                                       
   Yes vs. no (ref.)                                                                          0.84 (0.53-1.32)   0.454                   \-                 \-         0.76 (0.52-1.11)   0.155      \-                 \-
  **Cigarette smoking**                                                                                                                                                                                                 
   Yes vs. no (ref.)                                                                          1.19 (0.80-1.78)   0.396                   \-                 \-         1.06 (0.76-1.49)   0.721      \-                 \-
  **WHO histologic type**                                                                                                                                                                                               
   III vs. I-II (ref.)                                                                        0.42 (0.21-0.84)   0.014                   0.47 (0.23-0.95)   0.034      0.48 (0.27-0.86)   0.015      0.50 (0.28-0.92)   0.025
  **Viral capsid antigen IgA^[a)](#tfn4-crt-2017-255){ref-type="table-fn"}^**                                                                                                                                           
   \< 1:80                                                                                    Reference                                  \-                            Reference                     \-                 
   1:80-1:320                                                                                 0.88 (0.56-1.40)   0.600                   \-                 \-         0.88 (0.59-1.29)   0.499      \-                 \-
   ≥ 1:640                                                                                    0.83 (0.47-1.47)   0.524                   \-                 \-         0.97 (0.61-1.54)   0.910      \-                 \-
  **Early antigen IgA^[a)](#tfn4-crt-2017-255){ref-type="table-fn"}^**                                                                                                                                                  
   \< 1:10                                                                                    Reference                                  \-                            Reference                     \-                 
   1:10-1:20                                                                                  0.96 (0.58-1.58)   0.864                   \-                 \-         0.79 (0.51-1.21)   0.279      \-                 \-
   ≥ 1:40                                                                                     0.89 (0.56-1.43)   0.638                   \-                 \-         0.88 (0.60-1.29)   0.520      \-                 \-
  **Epstein-Barr virus DNA titer (copy/mL)^[a)](#tfn4-crt-2017-255){ref-type="table-fn"}^**                                                                                                                             
   \< 10,000                                                                                  Reference                                  Reference                     Reference                     Reference          
   10,000-99,999                                                                              1.34 (0.86-2.08)   0.196                   1.14 (0.73-1.78)   0.561      1.48 (1.03-2.12)   0.036      1.34 (0.93-1.93)   0.123
   ≥ 100,000                                                                                  2.04 (1.17-3.56)   0.012                   1.90 (1.08-3.35)   0.026      2.08 (1.29-3.35)   0.003      2.00 (1.23-3.24)   0.005
  **Neutrophil-to-lymphocyte ratio^[a)](#tfn4-crt-2017-255){ref-type="table-fn"}^**                                                                                                                                     
   ≥ 2.35 vs. \< 2.35 (ref.)                                                                  1.20 (0.80-1.79)   0.380                   \-                 \-         1.42 (1.01-1.98)   0.041      1.40 (1.00-1.96)   0.050
  **Clinical stage (8th edition)^[b)](#tfn5-crt-2017-255){ref-type="table-fn"}^**                                                                                                                                       
   IVA vs. III (ref.)                                                                         3.12 (1.95-4.99)   \< 0.001                2.95 (1.83-4.74)   \< 0.001   2.23 (1.55-3.21)   \< 0.001   2.04 (1.41-2.95)   \< 0.001
  **Chemotherapy regimen**                                                                                                                                                                                              
   PF                                                                                         Reference                                  \-                            Reference                     \-                 
   TPF                                                                                        0.82 (0.50-1.35)   0.436                   \-                 \-         0.85 (0.56-1.28)   0.427      \-                 \-
   TP                                                                                         0.76 (0.45-1.28)   0.302                   \-                 \-         0.73 (0.47-1.14)   0.166      \-                 \-
  **IC-1--induced neutropenia**                                                                                                                                                                                         
   Absent                                                                                     Reference                                  Reference                     Reference                     Reference          
   Grade 1-2                                                                                  1.84 (1.15-2.96)   0.012                   1.86 (1.15-2.98)   0.011      1.63 (1.11-2.39)   0.012      1.63 (1.11-2.39)   0.012
   Grade 3-4                                                                                  2.25 (1.35-3.76)   0.002                   2.29 (1.38-3.83)   0.001      1.66 (1.07-2.55)   0.023      1.72 (1.11-2.66)   0.015
   Grade 3-4 vs. 1-2 (ref.)                                                                   1.22 (0.75-1.99)   0.420                   1.23 (0.76-2.00)   0.395      1.02 (0.66-1.56)   0.945      1.05 (0.68-1.61)   0.810

HR, hazard ratio; CI, confidence interval; AHR, adjusted hazard ratio; ref., reference; WHO, World Health Organization; PF, cisplatin--5-fluorouracil; TPF, docetaxel--cisplatin--5-fluorouracil; TP, docetaxel--cisplatin; IC-1, the first-cycle of induction chemotherapy.

All variables were measured before treatment,

8th edition of the Union for International Cancer Control/American Joint Committee on Cancer staging system.

###### 

Univariate analysis of IC-1--induced neutropenia, timing of neutropenia, number of myelosuppression events, and post-NLR~min~

  Variable                                                                     No. (%)      Overall survival   Disease-free survival                                                               
  ---------------------------------------------------------------------------- ------------ ------------------ ----------------------- ------------------ ------- ------ ------ ------------------ -------
  **IC-1--induced neutropenia**                                                                                                                                                                    
   Absent                                                                      253 (46.4)   95.6               88.0                    Reference                  84.4   79.7   Reference          
   Occurred                                                                    292 (53.6)   87.2               78.2                    2.00 (1.30-3.06)   0.001   75.5   69.8   1.64 (1.16-2.31)   0.005
  **Timing of neutropenia^[a)](#tfn6-crt-2017-255){ref-type="table-fn"}^**                                                                                                                         
   Absent                                                                      253 (46.4)   95.6               88.0                    Reference                  84.4   79.7   Reference          
   1st week                                                                    120 (22.0)   88.2               77.9                    2.10 (1.27-3.49)   0.004   75.6   68.9   1.68 (1.11-2.56)   0.015
   2nd week                                                                    118 (21.7)   88.8               79.9                    1.80 (1.06-3.07)   0.030   76.9   75.1   1.35 (0.86-2.13)   0.187
   3rd week                                                                    54 (9.9)     81.2               75.5                    2.20 (1.15-4.20)   0.017   71.9   60.5   2.20 (1.32-3.66)   0.002
   2nd vs. 1st week (ref.)                                                     \-           \-                 \-                      0.85 (0.50-1.67)   0.566   \-     \-     0.81 (0.50-1.30)   0.375
   3rd vs. 1st week (ref.)                                                     \-           \-                 \-                      1.05 (0.54-2.01)   0.894   \-     \-     1.30 (0.77-2.23)   0.323
   3rd vs. 2nd week (ref.)                                                     \-           \-                 \-                      1.22 (0.62-2.40)   0.564   \-     \-     1.61 (0.93-2.86)   0.088
  **Myelosuppression events^[b)](#tfn7-crt-2017-255){ref-type="table-fn"}^**                                                                                                                       
   Group 1 (none)                                                              150 (27.5)   95.2               86.6                    Reference                  83.1   78.1   Reference          
   Group 2 (one)                                                               215 (39.4)   92.5               83.6                    1.29 (0.75-2.23)   0.362   81.2   76.1   1.08 (0.96-1.67)   0.747
   Group 3 (two/three)                                                         180 (33.0)   86.0               78.6                    1.81 (1.06-3.09)   0.029   74.9   69.2   1.53 (1.00-2.35)   0.050
  **Post-NLR~min~**                                                                                                                                                                                
   \< 1.33                                                                     267 (49.0)   93.9               86.3                    Reference                  82.6   79.0   Reference          
   ≥ 1.33                                                                      278 (51.0)   88.4               79.4                    1.42 (0.95-2.13)   0.087   76.8   69.9   1.51 (1.08-2.12)   0.016

IC-1, the first cycle of induction chemotherapy; post-NLR~min~, minimal value of the post-treatment neutrophil-to-lymphocyte ratio; HR, hazard ratio; CI, confidence interval; ref., reference.

First day of IC-1 until most severe neutropenia,

Three myelosuppression events, i.e., neutropenia, anemia, and thrombocytopenia, were analyzed in this study.
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